Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092910 · ClinicalTrials.gov registry record · NA
Esteem Totally Implantable Hearing System
A NA study of Mild to Severe Sensorineural Hearing Loss, sponsored by Envoy Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
- 5
- Study locations
NCT01092910: Completed NA study of Mild to Severe Sensorineural Hearing Loss, sponsored by Envoy Medical Corporation.
NCT01092910 is a NA study of Mild to Severe Sensorineural Hearing Loss that has completed, run by Envoy Medical Corporation. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01092910, a NA study of Mild to Severe Sensorineural Hearing Loss, has completed, sponsored by Envoy Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
- 5
- Study locations
Study Summary
To evaluate the safety and efficacy of the Esteem Totally Implantable Hearing System in subjects suffering from mild to severe hearing loss.
Primary Outcome
Comparison of the speech reception threshold (SRT) using the Esteem System as compared to the pre-implant aided condition
Conditions Studied
Interventions
- DEVICE Esteem Totally Implantable Hearing System
Study Locations (5)
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Shohet Ear Associates - Newport Beach
North Carolina
- Surgical Care Affiliates - Greensboro
- The Ear Center of Greensboro - Greensboro
Massachusetts
- Lahey Clinic, Inc. - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-08 |
| Phase | NA |
What the finished NCT01092910 record still lists
NCT01092910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Mild to Severe Sensorineural Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Esteem Totally Implantable Hearing System is the first listed.
NCT01092910 lists 5 locations in 3 states (California, North Carolina, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01092910 about?
NCT01092910 is a clinical study titled "Esteem Totally Implantable Hearing System". To evaluate the safety and efficacy of the Esteem Totally Implantable Hearing System in subjects suffering from mild to severe hearing loss.
What is the current status of trial NCT01092910?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2008-01. Estimated completion is 2010-08.
What conditions does trial NCT01092910 study?
This clinical trial studies the following conditions: Mild to Severe Sensorineural Hearing Loss.
What interventions are being tested in trial NCT01092910?
The interventions under investigation include: Esteem Totally Implantable Hearing System (DEVICE).
Who is sponsoring clinical trial NCT01092910?
This trial is sponsored by Envoy Medical Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01092910 being conducted?
This trial has 5 study locations across California, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01092910's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia